Luteotropic effects of tamoxifen in infertile women

  • Kumamoto University ROR

Fertility and Sterility, 42(2), 223-227

DOI 10.1016/s0015-0282(16)48017-9 PMID 6430723

Abstract

Tamoxifen at a dose of 10 mg/day for 5 days was given to five infertile women in the luteal phase. Daily serum samples were obtained during the luteal phase for radioimmunoassay of progesterone (P), estradiol (E2), follicle-stimulating hormone, luteinizing hormone (LH), and prolactin levels. The integrated luteal phase concentrations of serum P and E2 before and after cycles of tamoxifen treatment increased from 87.8 +/- 16.2 ng/ml and 1120 +/- 164.4 pg/ml to 131.6 +/- 18.9 ng/ml and 1461 +/- 205.2 pg/ml, respectively (P less than 0.01 and P less than 0.05). No apparent increase in circulating LH levels was seen in one of the five cases, but this patient's serum P and E2 levels rose nonetheless. This suggests that the significant increase in circulating P and E2 induced by tamoxifen is not consistently associated with an increase in serum LH concentration.

Topics

tamoxifen luteotropic effect progesterone estradiol increase, tamoxifen luteal phase support infertile women, tamoxifen 10 mg luteal phase progesterone enhancement, Tajima tamoxifen luteotropic infertility, luteal phase defect tamoxifen anti-estrogen treatment, tamoxifen serum progesterone estradiol integrated luteal concentration, luteal phase insufficiency tamoxifen LH independent mechanism, anti-estrogen luteal support corpus luteum function, tamoxifen progesterone increase without LH elevation, selective estrogen receptor modulator luteal phase therapy
PMID 6430723 6430723 DOI 10.1016/s0015-0282(16)48017-9 10.1016/s0015-0282(16)48017-9

Cite this article

Tajima, C. (1984). Luteotropic effects of tamoxifen in infertile women. *Fertility and sterility*, *42*(2), 223-227. https://doi.org/10.1016/s0015-0282(16)48017-9

Related articles